WO1995004571A1 - Implantable drug delivery means - Google Patents

Implantable drug delivery means Download PDF

Info

Publication number
WO1995004571A1
WO1995004571A1 PCT/AU1994/000469 AU9400469W WO9504571A1 WO 1995004571 A1 WO1995004571 A1 WO 1995004571A1 AU 9400469 W AU9400469 W AU 9400469W WO 9504571 A1 WO9504571 A1 WO 9504571A1
Authority
WO
WIPO (PCT)
Prior art keywords
reservoir
delivery
implantable drug
pump
drug delivery
Prior art date
Application number
PCT/AU1994/000469
Other languages
French (fr)
Inventor
Thomas John Berrigan
Original Assignee
Thomas John Berrigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas John Berrigan filed Critical Thomas John Berrigan
Priority to DE69429434T priority Critical patent/DE69429434T2/en
Priority to EP94923602A priority patent/EP0714316B1/en
Priority to BR9407238A priority patent/BR9407238A/en
Priority to AT94923602T priority patent/ATE210474T1/en
Priority to RU96105069A priority patent/RU2149028C1/en
Priority to NZ269505A priority patent/NZ269505A/en
Priority to AU73787/94A priority patent/AU684811B2/en
Priority to US08/591,450 priority patent/US5871478A/en
Priority to JP7506108A priority patent/JPH09501336A/en
Publication of WO1995004571A1 publication Critical patent/WO1995004571A1/en
Priority to US10/171,222 priority patent/US7018375B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A61M5/1428—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with manual pumping action
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/12—Pressure infusion

Definitions

  • THIS INVENTION resides in a subcutaneously implantable drug delivery means.
  • Such devices have comprised pumps driven by a power source, and which controls the delivery of drug to the body. Some of these pumps may be mounted externally to the body and are connected to a catheter introduced to a the body of the patient. Other devices have comprised a pump which is mounted subcutaneously to the body of the patient and which delivers a drug to the body at a desired location. Such devices however suffer the disadvantage in that they are quite expensive and that they utilise a power source in order to effect the delivery of the drug. In the event of the failure of the power source, the pump must be replaced.
  • the power source has in the past taken a variety of forms including utilisation of a phase-change fluid as is the case of a device marketed under the Trade Mark "INFUSAID".
  • a manually operated pump which may be mounted externally to the body or subcutaneously in the body of the patient whereby the pump can be activated by the patient for the delivery of the drug as need arises for that drug.
  • Examples of such devices are disclosed in US Patents 4,588,394, 4,681,560 and, 5,085,644 the contents of which are included herein by reference, and comprise devices whereby a pumping chamber is connected via catheter directly into the body and derives its source of drug from a holding reservoir.
  • the pumping chambers are of the form whereby they are biassed to a maximum volume condition, and on activation by the patient it is moved to a minimum volume position.
  • a subcutaneous implantable drug delivery means comprising a holding reservoir, a pumping means, a delivery reservoir and an outlet, said holding reservoir being connected to said delivery reservoir through said pump, said pump being operable manually whereby on activation the fluid is transferred from the holding reservoir to the delivery reservoir, said delivery reservoir being formed to be resiliently expandable to a maximum volume, from a minimum volume said delivery reservoir being connected to the outlet through a flow restriction means which controls the flow to the outlet.
  • connection between the holding reservoir and the delivery reservoir only permits flow from the holding reservoir to the delivery reservoir while the volume of the delivery reservoir is less than its maximum volume, said connection having a control means to prevent further delivery of fluid to the delivery reservoir on it achieving its maximum volume.
  • control means comprises a first valve between the holding reservoir and the pump, and a second valve between the pump and the delivery reservoir, said first and second valves permitting unidirectional flow to the pump and delivery reservoir respectively when said delivery reservoir is not filled to its maximum volume and permitting flow to the holding reservoir on said delivery reservoir attaining its maximum volume.
  • control means incorporates a unidirectional flow first valve between the holding reservoir and pump, a chamber between the pump and the delivery reservoir, said chamber being resiliently expandable with the expandable portion of the wall of the chamber having a higher modulus of elasticity than the delivery reservoir.
  • control means may comprise a relief valve located between the delivery reservoir and the holding reservoir which will permit flow from the delivery reservoir to the holding reservoir on the fluid pressure in the delivery reservoir exceeding a predetermined pressure.
  • flow restriction means comprises a single passageway and a filter located upstream from the passageway.
  • the flow restriction means is formed with a plurality of flow pathways.
  • the flow restriction means may comprise a plurality of capillary passageways.
  • the flow restriction means comprises a porous element.
  • the porous element can be formed of glass, ceramic or a like inert material.
  • Fig 1 is a schematic arrangement of the first embodiment
  • Fig 2 is a schematic arrangement of the second embodiment.
  • Each of the embodiments are intended as subcutaneous implantable drug delivery means which are formed of a suitable material to enable the implantation within a body cavity without the danger of formation of adhesions or like conditions.
  • the first embodiment as shown at Fig 1 comprises a holding reservoir 11 which is associated with a injection port 12 which is also mounted within the body and which is adapted to receive the needle of an injection syringe whereby the holding reservoir 11 can be filled.
  • the injection port 12 is connected through a filter 13 by means of double inlet duct 14.
  • An example of a suitable part is disclosed in US patent 5,137,529 the contents of which are incorporated herein by reference.
  • the delivery means further comprises a pump 15 which is connected to the holding reservoir 11 through a first delivery line 16. The flow of fluid through the first delivery line 16 to the pump 15, is controlled by means of a first valve 17.
  • the pump comprises a patient activated pump which is located in a body cavity of the patient such that it is accessible to be manipulated by the patient.
  • the pump comprises a chamber which is biassed to a maximum volume condition whereby on depression of the chamber as a result of manipulation by the patient, the chamber is caused to decrease in volume to deliver the contents of the chamber.
  • the pump 15 is connected to a delivery reservoir 18 through a second delivery line 19.
  • the flow of fluid from the pump 15 to the delivery reservoir 18 is controlled by means of a second valve 20.
  • the delivery reservoir 18 is formed to be resiliently expandable or self inflating. To achieve this, at least a portion of the wall of the delivery reservoir 18 is resiliently expandable such that the delivery reservoir can be inflated.
  • the first valve 17 is essentially a unidirectional valve whereby there can be unidirectional flow, from the holding reservoir 11 to the chamber of the pump 15.
  • the second valve 20 is primarily a unidirectional valve whereby there is a unidirectional flow of fluid from the chamber of the pump 15 to the delivery reservoir 18.
  • the delivery reservoir is provided with a limiting means which serves to limit the volume the delivery reservoir to a maximum whereby the delivery reservoir 18 is capable of expanding from a minimum volume condition to a maximum condition and whereby during such period of expansion a pressure is induced on the contents of the delivery reservoir by the resilient portion of the wall of the delivery chamber which is substantially constant throughout the expansion range of the delivery reservoir.
  • the means of controlling the maximum volume of the delivery reservoir may comprise a rigid container which surrounds the delivery reservoir 18 and which limits the expansion of the delivery reservoir beyond a maximum volume.
  • Another alternative embodiment may comprise utilisation of reinforcing ribs or fibres accommodated within the expandable portion of the wall of the delivery reservoir which enables resilient expansion of that portion of the wall to a position corresponding to the maximum volume position of the delivery reservoir in order that there is substantially little expansion beyond that point.
  • the means for controlling the maximum volume of the delivering reservoir may comprise a flexible enclosure having non expandable walls. The enclosure may be formed of a suitable cloth or mesh.
  • the first and second valves 17 and 20, while being unidirectional to allow for the delivery of fluid from the holding reservoir to the pump 15 and then to the delivery reservoir 18 are able to be rendered substantially bidirectional or unidirectional in the opposite direction at pressures above a predetermined pressure.
  • Such valves are designed to allow flow in one direction at a specified primary pressure and then in the other direction at a secondary pressure. The effect of such is that on the delivery reservoir 18 attaining its maximum volume a back pressure is induced in the second delivery line 19, and then subsequently within the chamber of the pump 15 and the portion of the first delivery line 16 between the first valve 17 and the pump 15.
  • the relief property of the second valve 20 ensures that the pressure that can be induced within the delivery reservoir cannot exceed a predetermined level and this serves to prevent inflation of the delivery reservoir 18 beyond its maximum volume.
  • This relief property of the first valve 17 also serves to ensure that on activation of the pump 15 when the delivery reservoir 18 is at it's maximum volume the contents of the chamber of the pump chamber 15 will be returned to the holding reservoir 11.
  • the delivery reservoir 18 is connected to an outlet 21 which may take any desired form according to the application of the delivery means through an outlet line 22.
  • the outlet line 22 is provided with a flow restriction means 23 which comprises a means of ensuring a controlled flow from the delivery reservoir 18 to the outlet 21.
  • the flow restriction means is formed with a plurality of passageways and may comprise an element having a plurality of capillary passageways or may comprise a porous element formed of glass, ceramic or a like inert material which is able to withstand the pressure created in the outlet line 22 by the delivery reservoir 18 such that a controlled quantity of fluid is allowed to pass through the flow restriction means.
  • the difference in volume of the delivery reservoir 18 between its minimum volume condition and its maximum volume condition is such that it is able to deliver the drug to the outlet 21 by means of the flow restriction means 23 over an extensive period of time.
  • the embodiment is mounted subcutaneously within the body of the patient with the injection port 12 being located at an appropriate injection site on the body and with the pump 15 located in a position at which it is accessible to the patient (e.g. above the sternum).
  • the outlet 21 is located in the appropriate portion of the body according to the application of the embodiment.
  • the dimensions of the device are such that the embodiment can be introduced into the body through a single small incision.
  • the pump 15 is then operated by the patient, by repetitive depression of the chamber of the pump 15 such that fluid is caused to flow from the holding reservoir, through the first delivery means 16, past the first valve 17, into the chamber of the pump 15, past the second valve 20 and through the second delivery lines 19 to the delivery reservoir 18.
  • the delivery reservoir 18 achieving its maximum volume any further activation of the pump 15 by the patient will not cause any further delivery into the delivery reservoir 18.
  • the delivery reservoir 18 has sufficient fluid introduced into it cause it to expand beyond its minimum volume, a pressure will be exerted upon that fluid which will cause delivery to the outlet 21 through the flow restriction means 23.
  • the rate of delivery is substantially constant. In use the patient would be instructed to activate the pump 15 at periods well short to the period of time required for the delivery reservoir 18 to contract from its maximum volume to its minimum volume such that the delivery reservoir 18 will maintain a volume corresponding substantially close to its maximum volume.
  • the drug is introduced into the patient from the outlet 21 at a substantially constant rate throughout its operating life.
  • the flow restriction means 23 is provided with a plurality of passageways, the blockage of any one or more passageways does not prevent continued flow of fluid to the outlet 21 which insures that the embodiment can continue operating in the event of any such partial blockage.
  • the second embodiment as shown in Figure 2 is of almost similar form to that of Figure 1 and the description of the first embodiment is directly applicable to the second embodiment. As a result the same reference numerals have been used in Figure 1 for corresponding components.
  • the difference between the first and second embodiments comprises the presence of a relief chamber 30 between the chamber of the pump 15 and the second valve 20.
  • the first valve 17 and second valve 20 may comprise bidirectional valves of the form utilised in the first embodiment or alternatively may comprise unidirectional valves.
  • the relief chamber 30 is formed to be resiliently expandable and the expandable walls of the chamber have a modulus of elasticity which is greater than that of the delivery reservoir 18. The effect of such is that on activation of the pump 15 causing the delivery of fluid to the chamber from the pump the delivery reservoir 18 is inflated in preference to the relief chamber 30 until such time as the delivery chamber 18 has achieved its maximum volume.
  • the back pressure created within the second delivery line 19 is such that as the pump 15 is activated causing collapse of its chamber so the relief chamber 30 is caused to inflate.
  • the fluid within the relief chamber is caused to return to the chamber of the pump 15 from the relief reservoir 30. Any continued activation of the pump 15 will merely cause inflation of the relief chamber 30 rather than any expansion of the delivery reservoir 18.
  • a third embodiment comprises a device of similar form to that of the first embodiment shown in Figure 1 except the first and second valves are conventional unidirectional valves.
  • the delivering reservoir is connected to the holding reservoir through a third valve comprising a relief valve which will open on the pressure in the delivering chamber exceeding a predetermined level. The pressure at which the relief valve will then correspond to the pressure which will be indicated after the delivery chamber has attained its maximum volume.
  • a fourth embodiment may take the form of any of the previous embodiments except that the flow restriction means comprises a single capillary having a filter upstream from the capillary to prevent blockage of the capillary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Processing Of Solid Wastes (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A subcutaneous drug delivery means which comprises a holding reservoir (11), a pumping means (15), a delivery reservoir (18) and an outlet (21). The holding reservoir (11) is connected to the delivery reservoir (18) through the pump (15) which is operable manually to deliver fluid from the holding reservoir (11) to the delivery reservoir (18). The delivery reservoir (18) is resiliently expandable from a minimum volume to a maximum volume and is connected to the outlet (21) through a flow restriction means (23) which controls flow to the outlet.

Description

"IMPLANTABLE DRUG DELIVERY MEANS"
THIS INVENTION resides in a subcutaneously implantable drug delivery means.
In the treatment of patients it is often desirable to provide a means whereby a drug or like agent can be introduced in a controlled manner over an extensive period of time. With the conventional intake of drugs and the like by means of periodic ingestion of a capsule or tablet or periodic injection there is usually an initial increase in the amount of the active agent in the body which is then reduced over a period of time until the next tablet is taken or injection given.
In many cases it is preferable to provide an intake of drug in a controlled manner such that the amount of drug in the body remains substantially constant. This is particularly the case in the treatment of patients suffering constant pain such as in the case of terminally ill patients who require a constant amount of an analgesic to be administered in order for them to be able to withstand the pain.
In the past several devices have been proposed for controlling the introduction of the drug into a body whereby it can be delivered in a controlled manner over a period of time. Such devices have comprised pumps driven by a power source, and which controls the delivery of drug to the body. Some of these pumps may be mounted externally to the body and are connected to a catheter introduced to a the body of the patient. Other devices have comprised a pump which is mounted subcutaneously to the body of the patient and which delivers a drug to the body at a desired location. Such devices however suffer the disadvantage in that they are quite expensive and that they utilise a power source in order to effect the delivery of the drug. In the event of the failure of the power source, the pump must be replaced. The power source has in the past taken a variety of forms including utilisation of a phase-change fluid as is the case of a device marketed under the Trade Mark "INFUSAID".
Other delivery devices have comprised a manually operated pump which may be mounted externally to the body or subcutaneously in the body of the patient whereby the pump can be activated by the patient for the delivery of the drug as need arises for that drug. Examples of such devices are disclosed in US Patents 4,588,394, 4,681,560 and, 5,085,644 the contents of which are included herein by reference, and comprise devices whereby a pumping chamber is connected via catheter directly into the body and derives its source of drug from a holding reservoir. The pumping chambers are of the form whereby they are biassed to a maximum volume condition, and on activation by the patient it is moved to a minimum volume position. In the case of 5,085,644 the re-entry of the drug into the pumping chamber is controlled by means of a capillary such that the pump is only able to deliver a full volume after a predetermined period of time. The disadvantage with this form of delivery means however is that drug levels within the body will vary periodically whereby on activation of the pump, the drug level within the body initially has a high level which then allowed to decay over a period of time until the pump is reactivated.
It is an object of this invention to provide an implantable drug delivery means whereby the delivery of the drug to the patient can be controlled in order that there is a substantially constant delivery of the drug without the need for any form of a power source.
In one form the invention resides in a subcutaneous implantable drug delivery means comprising a holding reservoir, a pumping means, a delivery reservoir and an outlet, said holding reservoir being connected to said delivery reservoir through said pump, said pump being operable manually whereby on activation the fluid is transferred from the holding reservoir to the delivery reservoir, said delivery reservoir being formed to be resiliently expandable to a maximum volume, from a minimum volume said delivery reservoir being connected to the outlet through a flow restriction means which controls the flow to the outlet.
According to a preferred feature of the invention, the connection between the holding reservoir and the delivery reservoir, only permits flow from the holding reservoir to the delivery reservoir while the volume of the delivery reservoir is less than its maximum volume, said connection having a control means to prevent further delivery of fluid to the delivery reservoir on it achieving its maximum volume. In one form the control means comprises a first valve between the holding reservoir and the pump, and a second valve between the pump and the delivery reservoir, said first and second valves permitting unidirectional flow to the pump and delivery reservoir respectively when said delivery reservoir is not filled to its maximum volume and permitting flow to the holding reservoir on said delivery reservoir attaining its maximum volume. According to an alternative form the control means incorporates a unidirectional flow first valve between the holding reservoir and pump, a chamber between the pump and the delivery reservoir, said chamber being resiliently expandable with the expandable portion of the wall of the chamber having a higher modulus of elasticity than the delivery reservoir. In another form the control means may comprise a relief valve located between the delivery reservoir and the holding reservoir which will permit flow from the delivery reservoir to the holding reservoir on the fluid pressure in the delivery reservoir exceeding a predetermined pressure. According to a preferred feature the flow restriction means comprises a single passageway and a filter located upstream from the passageway.
According to a preferred feature of the invention the flow restriction means is formed with a plurality of flow pathways. In one form the flow restriction means may comprise a plurality of capillary passageways. In one form the flow restriction means comprises a porous element. The porous element can be formed of glass, ceramic or a like inert material.
The invention would be more fully understood in the light of the following description of one specific embodiment. The description is made with reference to the accompanying drawings of which:
Fig 1 is a schematic arrangement of the first embodiment; and
Fig 2 is a schematic arrangement of the second embodiment.
Each of the embodiments are intended as subcutaneous implantable drug delivery means which are formed of a suitable material to enable the implantation within a body cavity without the danger of formation of adhesions or like conditions.
The first embodiment as shown at Fig 1 comprises a holding reservoir 11 which is associated with a injection port 12 which is also mounted within the body and which is adapted to receive the needle of an injection syringe whereby the holding reservoir 11 can be filled. The injection port 12 is connected through a filter 13 by means of double inlet duct 14. An example of a suitable part is disclosed in US patent 5,137,529 the contents of which are incorporated herein by reference. The delivery means further comprises a pump 15 which is connected to the holding reservoir 11 through a first delivery line 16. The flow of fluid through the first delivery line 16 to the pump 15, is controlled by means of a first valve 17. The pump comprises a patient activated pump which is located in a body cavity of the patient such that it is accessible to be manipulated by the patient. The pump comprises a chamber which is biassed to a maximum volume condition whereby on depression of the chamber as a result of manipulation by the patient, the chamber is caused to decrease in volume to deliver the contents of the chamber. The pump 15 is connected to a delivery reservoir 18 through a second delivery line 19. The flow of fluid from the pump 15 to the delivery reservoir 18 is controlled by means of a second valve 20. The delivery reservoir 18 is formed to be resiliently expandable or self inflating. To achieve this, at least a portion of the wall of the delivery reservoir 18 is resiliently expandable such that the delivery reservoir can be inflated.
The first valve 17 is essentially a unidirectional valve whereby there can be unidirectional flow, from the holding reservoir 11 to the chamber of the pump 15. The second valve 20 is primarily a unidirectional valve whereby there is a unidirectional flow of fluid from the chamber of the pump 15 to the delivery reservoir 18.
On the activation of the pump 15 by the patient causing the chamber of the pump 15 to collapse, fluid is delivered from the pump 15 into the delivery reservoir 18 and with repetitive activation of the pump 15 the delivery reservoir 18 is resiliently inflated to be filled by the drug.
The delivery reservoir is provided with a limiting means which serves to limit the volume the delivery reservoir to a maximum whereby the delivery reservoir 18 is capable of expanding from a minimum volume condition to a maximum condition and whereby during such period of expansion a pressure is induced on the contents of the delivery reservoir by the resilient portion of the wall of the delivery chamber which is substantially constant throughout the expansion range of the delivery reservoir.
The means of controlling the maximum volume of the delivery reservoir may comprise a rigid container which surrounds the delivery reservoir 18 and which limits the expansion of the delivery reservoir beyond a maximum volume. Another alternative embodiment may comprise utilisation of reinforcing ribs or fibres accommodated within the expandable portion of the wall of the delivery reservoir which enables resilient expansion of that portion of the wall to a position corresponding to the maximum volume position of the delivery reservoir in order that there is substantially little expansion beyond that point. In another embodiment the means for controlling the maximum volume of the delivering reservoir may comprise a flexible enclosure having non expandable walls. The enclosure may be formed of a suitable cloth or mesh.
The first and second valves 17 and 20, while being unidirectional to allow for the delivery of fluid from the holding reservoir to the pump 15 and then to the delivery reservoir 18 are able to be rendered substantially bidirectional or unidirectional in the opposite direction at pressures above a predetermined pressure. Such valves are designed to allow flow in one direction at a specified primary pressure and then in the other direction at a secondary pressure. The effect of such is that on the delivery reservoir 18 attaining its maximum volume a back pressure is induced in the second delivery line 19, and then subsequently within the chamber of the pump 15 and the portion of the first delivery line 16 between the first valve 17 and the pump 15. On further activation of the pump, the relief property of the second valve 20 ensures that the pressure that can be induced within the delivery reservoir cannot exceed a predetermined level and this serves to prevent inflation of the delivery reservoir 18 beyond its maximum volume. This relief property of the first valve 17 also serves to ensure that on activation of the pump 15 when the delivery reservoir 18 is at it's maximum volume the contents of the chamber of the pump chamber 15 will be returned to the holding reservoir 11.
The delivery reservoir 18 is connected to an outlet 21 which may take any desired form according to the application of the delivery means through an outlet line 22. The outlet line 22 is provided with a flow restriction means 23 which comprises a means of ensuring a controlled flow from the delivery reservoir 18 to the outlet 21. The flow restriction means is formed with a plurality of passageways and may comprise an element having a plurality of capillary passageways or may comprise a porous element formed of glass, ceramic or a like inert material which is able to withstand the pressure created in the outlet line 22 by the delivery reservoir 18 such that a controlled quantity of fluid is allowed to pass through the flow restriction means.
The difference in volume of the delivery reservoir 18 between its minimum volume condition and its maximum volume condition is such that it is able to deliver the drug to the outlet 21 by means of the flow restriction means 23 over an extensive period of time.
In use the embodiment is mounted subcutaneously within the body of the patient with the injection port 12 being located at an appropriate injection site on the body and with the pump 15 located in a position at which it is accessible to the patient (e.g. above the sternum). The outlet 21 is located in the appropriate portion of the body according to the application of the embodiment. The dimensions of the device are such that the embodiment can be introduced into the body through a single small incision.
Once in position, the holding chamber 11 is filled with the drug through the injection port 12. To activate the embodiment, the pump 15 is then operated by the patient, by repetitive depression of the chamber of the pump 15 such that fluid is caused to flow from the holding reservoir, through the first delivery means 16, past the first valve 17, into the chamber of the pump 15, past the second valve 20 and through the second delivery lines 19 to the delivery reservoir 18. On the delivery reservoir 18 achieving its maximum volume any further activation of the pump 15 by the patient will not cause any further delivery into the delivery reservoir 18. Once the delivery reservoir 18 has sufficient fluid introduced into it cause it to expand beyond its minimum volume, a pressure will be exerted upon that fluid which will cause delivery to the outlet 21 through the flow restriction means 23. The rate of delivery is substantially constant. In use the patient would be instructed to activate the pump 15 at periods well short to the period of time required for the delivery reservoir 18 to contract from its maximum volume to its minimum volume such that the delivery reservoir 18 will maintain a volume corresponding substantially close to its maximum volume.
As a result of the embodiment, the drug is introduced into the patient from the outlet 21 at a substantially constant rate throughout its operating life. Furthermore because the flow restriction means 23 is provided with a plurality of passageways, the blockage of any one or more passageways does not prevent continued flow of fluid to the outlet 21 which insures that the embodiment can continue operating in the event of any such partial blockage. The second embodiment as shown in Figure 2 is of almost similar form to that of Figure 1 and the description of the first embodiment is directly applicable to the second embodiment. As a result the same reference numerals have been used in Figure 1 for corresponding components.
The difference between the first and second embodiments comprises the presence of a relief chamber 30 between the chamber of the pump 15 and the second valve 20. In addition, the first valve 17 and second valve 20 may comprise bidirectional valves of the form utilised in the first embodiment or alternatively may comprise unidirectional valves. The relief chamber 30 is formed to be resiliently expandable and the expandable walls of the chamber have a modulus of elasticity which is greater than that of the delivery reservoir 18. The effect of such is that on activation of the pump 15 causing the delivery of fluid to the chamber from the pump the delivery reservoir 18 is inflated in preference to the relief chamber 30 until such time as the delivery chamber 18 has achieved its maximum volume. On the delivery reservoir achieving its maximum volume, the back pressure created within the second delivery line 19 is such that as the pump 15 is activated causing collapse of its chamber so the relief chamber 30 is caused to inflate. On pressure being taken from the pump 15 to cause the natural expansion of the chamber of the pump, the fluid within the relief chamber is caused to return to the chamber of the pump 15 from the relief reservoir 30. Any continued activation of the pump 15 will merely cause inflation of the relief chamber 30 rather than any expansion of the delivery reservoir 18.
A third embodiment comprises a device of similar form to that of the first embodiment shown in Figure 1 except the first and second valves are conventional unidirectional valves. In the case of the third embodiment, the delivering reservoir is connected to the holding reservoir through a third valve comprising a relief valve which will open on the pressure in the delivering chamber exceeding a predetermined level. The pressure at which the relief valve will then correspond to the pressure which will be indicated after the delivery chamber has attained its maximum volume.
A fourth embodiment may take the form of any of the previous embodiments except that the flow restriction means comprises a single capillary having a filter upstream from the capillary to prevent blockage of the capillary.
It should be appreciated that the scope of the present invention may not be limited with the scope of the embodiment described above.

Claims

THE CLAIMS defining this invention are as follows:
1. A subcutaneous implantable drug delivery means comprising a holding reservoir, a pumping means, a delivery reservoir and an outlet, said holding reservoir being connected to said delivery reservoir through said pump, said pump being operable manually whereby fluid is transferred from the holding reservoir to the delivery reservoir, said delivery reservoir being formed to be resiliently expandable from a minimum volume, to a maximum volume, said delivery reservoir being connected to the outlet through a flow restriction means which controls flow to the outlet.
2. An implantable drug delivery means as claimed in claim
1 wherein the connection between the holding reservoir and the delivery reservoir permits flow only from the holding reservoir to the delivery reservoir while the volume of the delivery reservoir is less than its maximum volume, said connection having a control means to prevent further delivery of fluid to the reservoir on the delivery chamber attaining its maximum volume.
3. An implantable drug delivery means as claimed in claim
2 wherein the control means comprises a first valve between the holding reservoir and the pump and a second valve between the pump and the delivery reservoir, said first and second valve permitting unidirectional flow to the pump and the delivery reservoir respectively, while said delivery reservoir is not filled to its maximum volume and permitting flow to the holding reservoir on said delivery reservoir attaining its maximum volume.
4. An implantable drug delivery means as claimed in claim 2 where in the control means comprises a one-way first valve between the holding reservoir and the pump, a relief chamber between the pump and the delivery reservoir, said relief chamber being resiliently expandable with the expandable portions of the wall of the chamber having a higher modulus of elasticity than the delivery reservoir.
5. An implantable drug delivery means as claimed in claim 4 wherein a second one-way valve is mounted between relief chamber and the delivery reservoir.
6. An implantable drug delivery means as claimed at claim 2 wherein the control means comprises a relief valve between the delivery reservoir and the holding reservoir which will permit flow from the delivery reservoir to the holding reservoir on the fluid pressure in the delivery reservoir exceeding a predetermined pressure.
7. An implantable drug delivery means as claimed at any one of the preceding claims wherein the flow restriction means is provided with a plurality of flow pathways.
8. An implantable drug delivery means as claimed in claim 7 wherein the flow restriction means comprise a plurality of capillary passageways.
9. An implantable drug delivery means as claimed in claim 7 wherein the flow restriction means comprises a porous element.
10. An implantable drug delivery means as claimed in claim 9 wherein the porous element is formed of glass, ceramic or like inert material.
11. An implantable drug delivery means as claimed at any one of claims 1 to 6 wherein the flow restriction means comprises a single passageway and a filter located upstream from the passageway.
12. An implantable drug delivery means as claimed at any one of the preceding claims wherein the delivery reservoir is enclosed by an enclosure having non expandable walls to limit the expansion of the delivery reservoir beyond the maximum volume.
13. An implantable drug delivery means as claimed at claim 12 wherein the walls of the enclosure are rigid.
14. An implantable drug delivery means as claimed at claim 12 wherein the walls of the enclosure are flexible.
15. An implantable drug delivery means as claimed at any one of claims 1 to 11 wherein the walls of the delivery reservoirs are adapted to be incapable of expansion beyond the maximum volume.
16. An implantable drug delivery means as claimed in anyone of the preceding claims wherein the pressure induced on the fluid within the delivery reservoir between its minimum static volume . condition and its maximum volume condition is substantially constant.
17. An implantable drub delivery means substantially as herein described.
PCT/AU1994/000469 1993-08-11 1994-08-11 Implantable drug delivery means WO1995004571A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE69429434T DE69429434T2 (en) 1993-08-11 1994-08-11 IMPLANTABLE DISPOSAL DEVICE
EP94923602A EP0714316B1 (en) 1993-08-11 1994-08-11 Implantable drug delivery means
BR9407238A BR9407238A (en) 1993-08-11 1994-08-11 Implantable drug delivery device
AT94923602T ATE210474T1 (en) 1993-08-11 1994-08-11 IMPLANTABLE DRUG DELIVERY DEVICE
RU96105069A RU2149028C1 (en) 1993-08-11 1994-08-11 Implanted drug delivery system (versions)
NZ269505A NZ269505A (en) 1993-08-11 1994-08-11 Drug delivery device comprising fluid delivery control means between a holding and a delivery reservoir
AU73787/94A AU684811B2 (en) 1993-08-11 1994-08-11 Drug delivery means
US08/591,450 US5871478A (en) 1993-08-11 1994-08-11 Implantable drug delivery means
JP7506108A JPH09501336A (en) 1993-08-11 1994-08-11 Implantable drug delivery means
US10/171,222 US7018375B2 (en) 1993-08-11 2002-06-12 Drug delivery device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM048393 1993-08-11
AUPM0483 1993-08-11

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08/591,450 A-371-Of-International US5871478A (en) 1993-08-11 1994-08-11 Implantable drug delivery means
US08591450 A-371-Of-International 1994-08-11
US09/186,729 Continuation-In-Part US6471686B1 (en) 1993-08-11 1998-11-04 Drug delivery device

Publications (1)

Publication Number Publication Date
WO1995004571A1 true WO1995004571A1 (en) 1995-02-16

Family

ID=3777122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1994/000469 WO1995004571A1 (en) 1993-08-11 1994-08-11 Implantable drug delivery means

Country Status (11)

Country Link
US (3) US5871478A (en)
EP (1) EP0714316B1 (en)
JP (1) JPH09501336A (en)
CN (1) CN1128957A (en)
AT (1) ATE210474T1 (en)
BR (1) BR9407238A (en)
CA (1) CA2168554A1 (en)
DE (1) DE69429434T2 (en)
NZ (1) NZ269505A (en)
RU (1) RU2149028C1 (en)
WO (1) WO1995004571A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015306A1 (en) * 1996-10-09 1998-04-16 Thomas John Berrigan Drug delivery means
AU727879B2 (en) * 1996-10-09 2001-01-04 Thomas John Berrigan Drug delivery means
US6471686B1 (en) 1993-08-11 2002-10-29 Thomas John Berrigan Drug delivery device
EP2026709A2 (en) * 2006-06-09 2009-02-25 Neurosystec Corporation Flow-induced delivery from a drug mass
US8814829B2 (en) 2010-08-12 2014-08-26 Baxter International Inc. Drug delivery device for fluid restricted patients
US9610398B2 (en) 2011-11-22 2017-04-04 Incube Labs, Llc Implantable solid-liquid drug delivery apparatus, formulations, and methods of use

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6139535A (en) * 1999-05-27 2000-10-31 Situs Corporation Method and apparatus for placement and activation of a medical device within a body cavity
US6471689B1 (en) * 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6638263B1 (en) * 1999-10-12 2003-10-28 Durect Corporation Regulation of drug delivery through flow diversion
CN100402100C (en) * 2001-06-01 2008-07-16 艾佛罗公司 Large volume bolus device and method
DE10157969C1 (en) 2001-11-27 2003-02-06 Biedermann Motech Gmbh Element used in spinal and accident surgery comprises a shaft joined to a holding element having a U-shaped recess with two free arms having an internal thread with flanks lying at right angles to the central axis of the holding element
ATE402724T1 (en) * 2002-02-18 2008-08-15 Danfoss As DEVICE FOR ADMINISTRATION OF A MEDICATION IN LIQUID FORM
US20040143213A1 (en) * 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US8114055B2 (en) * 2005-05-10 2012-02-14 Palyon Medical (Bvi) Limited Implantable pump with infinitely variable resistor
US7637892B2 (en) * 2005-05-10 2009-12-29 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8211060B2 (en) 2005-05-10 2012-07-03 Palyon Medical (Bvi) Limited Reduced size implantable pump
US8915893B2 (en) 2005-05-10 2014-12-23 Palyon Medical (Bvi) Limited Variable flow infusion pump system
WO2006127508A2 (en) * 2005-05-20 2006-11-30 Wilson Greatbatch Technologies Inc. Improved configuration for drug delivery systems
US11027058B2 (en) 2006-02-09 2021-06-08 Deka Products Limited Partnership Infusion pump assembly
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8579884B2 (en) 2006-02-09 2013-11-12 Deka Products Limited Partnership Infusion pump assembly
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US9492606B2 (en) 2006-02-09 2016-11-15 Deka Products Limited Partnership Apparatus, system and methods for an infusion pump assembly
EP1993633B1 (en) 2006-02-09 2016-11-09 Deka Products Limited Partnership Pumping fluid delivery systems and methods using force application assembly
US12070574B2 (en) 2006-02-09 2024-08-27 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US10010669B2 (en) * 2006-02-09 2018-07-03 Deka Products Limited Partnership Systems and methods for fluid delivery
ES2382449T3 (en) * 2006-06-13 2012-06-08 Carefusion 303, Inc. System and method for optimizing control of PCA and PCEA systems
EP2041214A4 (en) 2006-07-10 2009-07-08 Medipacs Inc Super elastic epoxy hydrogel
KR100697348B1 (en) * 2006-09-22 2007-03-20 한국기계연구원 Valve and micro fluid pump having the same
US7535991B2 (en) * 2006-10-16 2009-05-19 Oraya Therapeutics, Inc. Portable orthovoltage radiotherapy
WO2008047373A2 (en) * 2006-10-19 2008-04-24 Mfs Medical Flow Systems Ltd. Device and method for patient activated bolus administration
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
EP2121077A1 (en) 2007-02-09 2009-11-25 Deka Products Limited Partnership Automated insertion assembly
US8449500B2 (en) * 2007-11-16 2013-05-28 Baxter International Inc. Flow pulsatility dampening devices for closed-loop controlled infusion systems
EP2227635A2 (en) 2007-12-03 2010-09-15 Medipacs, Inc. Fluid metering device
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
WO2009088956A2 (en) * 2007-12-31 2009-07-16 Deka Products Limited Partnership Infusion pump assembly
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
JP5634269B2 (en) 2007-12-31 2014-12-03 デカ・プロダクツ・リミテッド・パートナーシップ Infusion pump assembly
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US20090275894A1 (en) * 2008-05-01 2009-11-05 Curtis Guy P Transvenous soaker catheter
US10265454B2 (en) * 2008-07-25 2019-04-23 Baxter International Inc. Dialysis system with flow regulation device
CN105056336B (en) * 2008-10-10 2019-09-13 医树专利有限公司 Infusion of drug
US20110313394A1 (en) * 2008-10-24 2011-12-22 Innerspace, Inc Sensor Controlled Flow Path For Providing Fluids To Patients
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
WO2011082272A2 (en) 2009-12-31 2011-07-07 Deka Products Limited Partnership Infusion pump assembley
WO2011091265A1 (en) 2010-01-22 2011-07-28 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
CA2789141C (en) 2010-02-05 2018-06-12 Deka Products Limited Partnership Infusion pump apparatus, method and system
US11660392B2 (en) 2010-02-05 2023-05-30 Deka Products Limited Partnership Devices, methods and systems for wireless control of medical devices
US9662438B2 (en) 2010-02-05 2017-05-30 Deka Products Limited Partnership Devices, methods and systems for wireless control of medical devices
US8366667B2 (en) 2010-02-11 2013-02-05 Baxter International Inc. Flow pulsatility dampening devices
US9211378B2 (en) 2010-10-22 2015-12-15 Cequr Sa Methods and systems for dosing a medicament
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
US8685106B2 (en) 2011-11-15 2014-04-01 Abraham Lin Method of a pharmaceutical delivery system for use within a joint replacement
JP2015500115A (en) * 2011-12-15 2015-01-05 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Reservoir or medicated module for drug delivery system, method of filling it, and assembly therefor
US8568360B2 (en) 2011-12-28 2013-10-29 Palyon Medical (Bvi) Limited Programmable implantable pump design
WO2013134519A2 (en) 2012-03-07 2013-09-12 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
WO2013138524A1 (en) 2012-03-14 2013-09-19 Medipacs, Inc. Smart polymer materials with excess reactive molecules
US9617020B2 (en) 2013-07-03 2017-04-11 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
FR3032264B1 (en) * 2015-02-02 2017-03-03 Degremont METHOD FOR MANAGING AIR FLOW OF A MECHANICAL SLUDGE DEHYDRATION, AND DEVICE THEREFOR
CN104758056B (en) * 2015-02-04 2018-08-17 深圳市罗伯医疗科技有限公司 A kind of fluid delivery system and surgery device
CN104740752A (en) * 2015-04-08 2015-07-01 四川大学华西第二医院 Implantable intelligent in-vivo drug use control device
EP3784312A1 (en) 2018-04-24 2021-03-03 DEKA Products Limited Partnership Apparatus and system for fluid delivery
US11524108B2 (en) 2019-11-12 2022-12-13 Infusaid Medical Mfg, Llc Cassette assembly for ambulatory drug pump
MX2024007131A (en) * 2021-12-13 2024-06-24 Becton Dickinson Co Pressure threshold detector for medical injector.
CN115227904B (en) * 2022-08-01 2023-07-04 南京竹海生物科技有限公司 Disposable local anesthesia analgesic system and use method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202696A1 (en) * 1985-05-21 1986-11-26 Applied Precision Limited Manually activated implantable device for dispensing therapeutic substances
WO1987006473A1 (en) * 1986-04-24 1987-11-05 Centre National De La Recherche Scientifique (Cnrs Rechargeable implantable device for dosed and repeated self-injection of medicament
EP0335671A1 (en) * 1988-03-29 1989-10-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Implantable drug delivery system
EP0342946A2 (en) * 1988-05-18 1989-11-23 BAXTER INTERNATIONAL INC. (a Delaware corporation) Implantable patient-activated fluid delivery device
EP0420620A2 (en) * 1989-09-26 1991-04-03 Infusaid Inc. Pressure regulator for implantable pump
EP0488701A1 (en) * 1990-11-29 1992-06-03 Minimed Inc., doing business as Minimed Technologies Liquid-vapour pressure reservoir for medication infusion pump

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525165A (en) * 1979-04-27 1985-06-25 The Johns Hopkins University Fluid handling system for medication infusion system
US4253501A (en) * 1979-11-09 1981-03-03 Ims Limited Transfer system
US4681560A (en) * 1984-03-16 1987-07-21 Pudenz-Schulte Medical Research Corp. Subcutaneous infusion reservoir and pump system
US4588394A (en) * 1984-03-16 1986-05-13 Pudenz-Schulte Medical Research Corp. Infusion reservoir and pump system
JPS63501195A (en) * 1985-08-06 1988-05-12 バクスター、インターナショナル、インコーポレイテッド Device for patient-controlled release of beneficial drugs
US4714462A (en) * 1986-02-03 1987-12-22 Intermedics Infusaid, Inc. Positive pressure programmable infusion pump
US4813951A (en) * 1987-05-20 1989-03-21 Joel Wall Self-actuated implantable pump
US5053031A (en) * 1988-03-29 1991-10-01 Baxter International Inc. Pump infusion system
US5137529A (en) 1990-02-20 1992-08-11 Pudenz-Schulte Medical Research Corporation Injection port
US5085644A (en) * 1990-04-02 1992-02-04 Pudenz-Schulte Medical Research Corporation Sterilizable medication infusion device with dose recharge restriction
BR9407238A (en) 1993-08-11 1996-09-24 Thomas John Berrigan Implantable drug delivery device
US5607418A (en) 1995-08-22 1997-03-04 Illinois Institute Of Technology Implantable drug delivery apparatus
IE77523B1 (en) * 1995-09-11 1997-12-17 Elan Med Tech Medicament delivery device
ATE242020T1 (en) * 1996-03-14 2003-06-15 Oneil Christine PATIENT-CONTROLLED FLOW REGULATION FOR A MEDICATION DELIVERY SYSTEM
AUPO295696A0 (en) 1996-10-09 1996-11-07 Berrigan, Thomas John Drug delivery means
US6355024B1 (en) * 1999-07-14 2002-03-12 Mallinckrodt Inc. Medical fluid delivery system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202696A1 (en) * 1985-05-21 1986-11-26 Applied Precision Limited Manually activated implantable device for dispensing therapeutic substances
WO1987006473A1 (en) * 1986-04-24 1987-11-05 Centre National De La Recherche Scientifique (Cnrs Rechargeable implantable device for dosed and repeated self-injection of medicament
EP0335671A1 (en) * 1988-03-29 1989-10-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Implantable drug delivery system
EP0342946A2 (en) * 1988-05-18 1989-11-23 BAXTER INTERNATIONAL INC. (a Delaware corporation) Implantable patient-activated fluid delivery device
EP0420620A2 (en) * 1989-09-26 1991-04-03 Infusaid Inc. Pressure regulator for implantable pump
EP0488701A1 (en) * 1990-11-29 1992-06-03 Minimed Inc., doing business as Minimed Technologies Liquid-vapour pressure reservoir for medication infusion pump

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471686B1 (en) 1993-08-11 2002-10-29 Thomas John Berrigan Drug delivery device
US7018375B2 (en) 1993-08-11 2006-03-28 Thomas John Berrigan Drug delivery device
WO1998015306A1 (en) * 1996-10-09 1998-04-16 Thomas John Berrigan Drug delivery means
AU727879B2 (en) * 1996-10-09 2001-01-04 Thomas John Berrigan Drug delivery means
US6319245B1 (en) 1996-10-09 2001-11-20 Thomas John Berrigan Drug delivery means
EP2026709A2 (en) * 2006-06-09 2009-02-25 Neurosystec Corporation Flow-induced delivery from a drug mass
EP2026709A4 (en) * 2006-06-09 2011-04-06 Neurosystec Corp Flow-induced delivery from a drug mass
US8814829B2 (en) 2010-08-12 2014-08-26 Baxter International Inc. Drug delivery device for fluid restricted patients
US9610398B2 (en) 2011-11-22 2017-04-04 Incube Labs, Llc Implantable solid-liquid drug delivery apparatus, formulations, and methods of use
US10172997B2 (en) 2011-11-22 2019-01-08 Incube Labs, Llc Implantable solid-liquid drug delivery apparatus, formulations, and methods of use
US10758668B2 (en) 2011-11-22 2020-09-01 Incube Labs, Llc Implantable solid-liquid drug delivery apparatus, formulations, and methods of use

Also Published As

Publication number Publication date
US5871478A (en) 1999-02-16
BR9407238A (en) 1996-09-24
EP0714316A1 (en) 1996-06-05
RU2149028C1 (en) 2000-05-20
CA2168554A1 (en) 1995-02-16
CN1128957A (en) 1996-08-14
US6471686B1 (en) 2002-10-29
ATE210474T1 (en) 2001-12-15
US7018375B2 (en) 2006-03-28
JPH09501336A (en) 1997-02-10
NZ269505A (en) 1999-03-29
EP0714316B1 (en) 2001-12-12
EP0714316A4 (en) 1997-05-21
DE69429434D1 (en) 2002-01-24
DE69429434T2 (en) 2002-08-22
US20020156463A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
US5871478A (en) Implantable drug delivery means
US6319245B1 (en) Drug delivery means
US5053031A (en) Pump infusion system
US4634427A (en) Implantable demand medication delivery assembly
CA2479706C (en) Implantable pump with adjustable flow rate
US6629950B1 (en) Fluid delivery system
IL122499A0 (en) Patient controlled drug delivery device
US8221354B2 (en) Infusion device with positive pressure elastic bladder reservoir
EP0291612B1 (en) Implantable pump.
US4687468A (en) Implantable insulin administration device
JPH0852222A (en) Medicine injection pump with improved pressure reservoir
DE60124671D1 (en) IMPLANTABLE REFRESHABLE INFUSION DEVICE
WO1997007840A1 (en) Implantable drug delivery apparatus
RU2238111C2 (en) Implantable system for carrying out controlled infusion
US5135497A (en) Large volume pressurized fluid dispenser
CA1333144C (en) Implantable drug delivery system
AU684811B2 (en) Drug delivery means
EP0177250A2 (en) Implantable insulin administration device
AU727879B2 (en) Drug delivery means
RU27786U1 (en) IMPLANTED SYSTEM FOR DOSED INFUSION

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193043.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 269505

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08591450

Country of ref document: US

Ref document number: 2168554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994923602

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994923602

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994923602

Country of ref document: EP